TScan Therapeutics, Inc. Common Stock

$0.9206
USD
Last updated on --.
24h volume380.05K
24h highest0.95850 USD
24h lowest0.90430 USD
24h Price movement-0.36%

TCRX recent prices

24 Hours
-0.36%-$0.0033
30 days
-14.96%-$0.166
60 days
-10.94%-$0.116
90 days
-10.94%-$0.116

Key data

Previous close0.92390 USD
Market cap64.17M USD
Volume380.05K
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)-1.9000 USD
Net income (FY)-124.31M USD
Revenue (FY)9.14M USD
Last report dateMay 6, 2026

About TScan Therapeutics, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
HeadquartersWALTHAM
Employees (FY)142.00
Revenue per employee (FY)64.34K USD
Net income per employee (FY)-875.39K USD
Listed onNasdaq
Official website

TCRX conversion tables

TCRXTCRX
USDUSD
0.5 TCRX0.4603 USD
1 TCRX0.9206 USD
5 TCRX4.603 USD
10 TCRX9.206 USD
USDUSD
TCRXTCRX
0.5 USD0.54312 TCRX
1 USD1.086 TCRX
5 USD5.431 TCRX
10 USD10.86 TCRX

FAQ

TCRX is trading at $0.9206, -0.36% over the last 24 hours. Track live moves on the price chart at the top of this page.
The TCRX stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. TCRX is currently trading at $0.9206, -0.36% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on TCRX price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. TCRX's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from TCRX; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against TCRX's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
TScan Therapeutics, Inc. Common Stock's market cap is currently 64.17M USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume380.05K
24h highest0.95850 USD
24h lowest0.90430 USD
24h Price movement-0.36%
TCRXTCRX
USDUSD
Start trade with TCRX Perpetual